SCHEMBL16570777

SCHEMBL16570777

O=S(=O)(c1ccccc1Cl)n1ncc2cnc(Nc3ccc(N4CCNCC4)cc3)nc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 5/20 0.59
CDK4 P11802 7/20 0.52
CCND1 P24385 5/20 0.52
CCNA2 P20248 3/20 0.52
CDK2 P24941 3/20 0.52
MAPK8 P45983 1/20 0.51
MAPK9 P45984 1/20 0.51
MAPK10 P53779 1/20 0.51
FGFR1 P11362 3/20 0.50
FGFR2 P21802 3/20 0.50
FGFR3 P22607 3/20 0.50
CCND2 P30279 3/20 0.50
CCND3 P30281 3/20 0.50
CCNE2 O96020 1/20 0.50
CCNE1 P24864 1/20 0.50
CCNA1 P78396 1/20 0.50
JAK2 O60674 3/20 0.49
BRD4 O60885 3/20 0.49
JAK1 P23458 2/20 0.49
BRD2 P25440 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570933 0.88 FGFR4 (0.55) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16571009 0.88 FGFR4 (0.55) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16570934 0.88 FGFR4 (0.55) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16570850 0.87 FGFR4 (0.57) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16570075 0.87 FGFR4 (0.62) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16570625 0.86 BRD4 (0.53) FGFR4CDK4CCND1CDK2MAPK9
SCHEMBL16580902 0.85 FGFR4 (0.80) FGFR4JAK2BRD4JAK1BRD2
SCHEMBL16570263 0.85 JAK2 (0.49) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16570470 0.85 FGFR4 (0.49) FGFR4CDK4CCND1CCNA2CDK2
SCHEMBL16571082 0.79 FGFR4 (0.70) FGFR4JAK2BRD4JAK1BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN FGFR4 385/4885CDK4 243/4885CCND1 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.